Novel agents for advanced pancreatic cancer

Oncotarget. 2015 Nov 24;6(37):39521-37. doi: 10.18632/oncotarget.3999.

Abstract

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.

Keywords: IGF-1R; pancreatic cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Immunoconjugates / therapeutic use*
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / metabolism
  • Signal Transduction / drug effects*
  • Small Molecule Libraries / therapeutic use*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • Small Molecule Libraries